{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:20:35Z","timestamp":1787019635245,"version":"build-2736575974"},"reference-count":32,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We performed a multicenter retrospective analysis across 10 US academic medical centers to evaluate treatment patterns and outcomes in patients age \u226560 years with classic Hodgkin lymphoma (cHL) from 2010-2018. Among 244 eligible patients, median age was 68, 63% had advanced stage (III\/IV), 96% had Eastern Cooperative Oncology Group performance status (PS) 0-2, and 12% had documented loss of \u22651 activity of daily living (ADL). Medical comorbidities were assessed by the Cumulative Illness Rating Scale\u2013Geriatric (CIRS-G), where n = 44 (18%) had total scores \u226510. Using multivariable Cox models, only ADL loss predicted shorter progression-free (PFS; hazard ratio [HR] 2.13, P = .007) and overall survival (OS; HR 2.52, P = .02). Most patients (n = 203, 83%) received conventional chemotherapy regimens, including doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD; 56%), AVD (14%), and AVD with brentuximab vedotin (BV; 9%). Compared to alternative therapies, conventional regimens significantly improved PFS (HR 0.46, P = .0007) and OS (HR 0.31, P = .0003). Survival was similar following conventional chemotherapy in those ages 60-69 vs \u226570: PFS HR 0.88, P = .63; OS HR 0.73, P = .55. Early treatment discontinuation due to toxicity was more common with CIRS-G \u226510 (28% vs 12%, P = .016) or documented geriatric syndrome (28% vs 13%, P = .02). A competing risk analysis demonstrated improved disease-related survival with conventional therapy (HR 0.29, P = .02) and higher mortality from causes other than disease or treatment with high CIRS-G or geriatric syndromes. This study suggests conventional chemotherapy regimens remain a standard of care in fit older patients with cHL, and highlights the importance of geriatric assessments in defining fitness for cHL therapy going forward.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004645","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T10:08:08Z","timestamp":1630058888000},"page":"3623-3632","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma"],"prefix":"10.1182","volume":"5","author":[{"given":"Victor M.","family":"Orellana-Noia","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA;"},{"name":"Division of Hematology\/Oncology, University of Virginia, Charlottesville, VA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0234-139X","authenticated-orcid":false,"given":"Krista","family":"Isaac","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Virginia, Charlottesville, VA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-4675","authenticated-orcid":false,"given":"Mary-Kate","family":"Malecek","sequence":"additional","affiliation":[{"name":"Department of Medicine, Washington University School of Medicine, St. Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8470-394X","authenticated-orcid":false,"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Department of Medicine, Washington University School of Medicine, St. Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7603-6454","authenticated-orcid":false,"given":"Timothy J.","family":"Voorhees","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1346-3157","authenticated-orcid":false,"given":"Natalie S.","family":"Grover","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6536-1291","authenticated-orcid":false,"given":"Steven R.","family":"Hwang","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8358-5953","authenticated-orcid":false,"given":"N. Nora","family":"Bennani","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4467-1856","authenticated-orcid":false,"given":"Rachel","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9865-4517","authenticated-orcid":false,"given":"Eric","family":"Mou","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, CA;"},{"name":"Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City IA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana H.","family":"Advani","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-6481","authenticated-orcid":false,"given":"Jordan","family":"Carter","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, New Brunswick, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin A.","family":"David","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, New Brunswick, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatcher J.","family":"Ballard","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Churnetski","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Magarelli","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center, Hackensack Meridian Health School of Medicine, Hackensack, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana A.","family":"Feldman","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center, Hackensack Meridian Health School of Medicine, Hackensack, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Evens","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, New Brunswick, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9487-8345","authenticated-orcid":false,"given":"Craig A.","family":"Portell","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Virginia, Charlottesville, VA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"issue":"2","key":"2021092415294134300_B1","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1046\/j.1365-2141.2002.03815.x","article-title":"Hodgkin\u2019s disease in the elderly: a population-based study","volume":"119","author":"Stark","year":"2002","journal-title":"Br J Haematol."},{"issue":"22","key":"2021092415294134300_B2","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2005.11.080","article-title":"Hodgkin\u2019s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin\u2019s Study Group","volume":"23","author":"Engert","year":"2005","journal-title":"J Clin Oncol."},{"issue":"2","key":"2021092415294134300_B3","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.16525","article-title":"First-line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)-Medicare population-based study","volume":"190","author":"Rodday","year":"2020","journal-title":"Br J Haematol."},{"issue":"6","key":"2021092415294134300_B4","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J Clin Oncol."},{"issue":"4","key":"2021092415294134300_B5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med."},{"issue":"3","key":"2021092415294134300_B6","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","article-title":"A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era","volume":"119","author":"Evens","year":"2012","journal-title":"Blood."},{"issue":"1","key":"2021092415294134300_B7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/bjh.15652","article-title":"The treatment of older Hodgkin lymphoma patients","volume":"184","author":"B\u00f6ll","year":"2019","journal-title":"Br J Haematol."},{"issue":"1","key":"2021092415294134300_B8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br J Haematol."},{"issue":"26","key":"2021092415294134300_B9","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood."},{"issue":"26","key":"2021092415294134300_B10","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","article-title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged \u226560 years with HL","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood."},{"key":"2021092415294134300_B11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/blood-2019-124866","article-title":"Phase 2 study of frontline brentuximab vedotin plus nivolumab in patients with Hodgkin lymphoma aged \u226560 years [abstract]","volume":"134","author":"Yasenchak","year":"2019","journal-title":"Blood."},{"issue":"22","key":"2021092415294134300_B12","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol."},{"issue":"3","key":"2021092415294134300_B13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.leukres.2013.12.018","article-title":"The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review","volume":"38","author":"Hamaker","year":"2014","journal-title":"Leuk Res."},{"issue":"25","key":"2021092415294134300_B14","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1182\/blood-2011-12-396556","article-title":"Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study","volume":"119","author":"Proctor","year":"2012","journal-title":"Blood."},{"issue":"30","key":"2021092415294134300_B15","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J Clin Oncol."},{"issue":"4","key":"2021092415294134300_B16","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.1998.16.4.1582","article-title":"Comorbidity and functional status are independent in older cancer patients","volume":"16","author":"Extermann","year":"1998","journal-title":"J Clin Oncol."},{"issue":"24","key":"2021092415294134300_B17","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J Clin Oncol."},{"issue":"3","key":"2021092415294134300_B18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0165-1781(92)90005-N","article-title":"Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale","volume":"41","author":"Miller","year":"1992","journal-title":"Psychiatry Res."},{"issue":"4","key":"2021092415294134300_B19","first-page":"1087","article-title":"Hodgkin\u2019s disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen","volume":"20","author":"Weekes","year":"2002","journal-title":"J Clin Oncol."},{"issue":"4","key":"2021092415294134300_B20","first-page":"438","article-title":"Hodgkin\u2019s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis","volume":"88","author":"Landgren","year":"2003","journal-title":"Haematologica."},{"issue":"446","key":"2021092415294134300_B21","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc."},{"issue":"5","key":"2021092415294134300_B22","doi-asserted-by":"crossref","first-page":"608","DOI":"10.6004\/jnccn.2017.0064","article-title":"Hodgkin lymphoma version 1.2017","volume":"15","author":"Hoppe","year":"2017","journal-title":"J Natl Compr Canc Netw."},{"issue":"4","key":"2021092415294134300_B23","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3109\/10428194.2014.953142","article-title":"Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL)","volume":"56","author":"Tucci","year":"2015","journal-title":"Leuk Lymphoma."},{"issue":"5","key":"2021092415294134300_B24","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol."},{"issue":"20","key":"2021092415294134300_B25","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1182\/blood-2017-05-736975","article-title":"Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma [published correction appears in Blood. 2018;131(9):1037]","volume":"130","author":"Lin","year":"2017","journal-title":"Blood."},{"issue":"18","key":"2021092415294134300_B26","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood-2015-11-681064","article-title":"Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials","volume":"127","author":"B\u00f6ll","year":"2016","journal-title":"Blood."},{"issue":"1","key":"2021092415294134300_B27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jgo.2019.09.009","article-title":"Advancing age and the risk of bleomycin pulmonary toxicity in a largely older cohort of patients with newly diagnosed Hodgkin Lymphoma","volume":"11","author":"Thomas","year":"2020","journal-title":"J Geriatr Oncol."},{"issue":"11","key":"2021092415294134300_B28","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1200\/JCO.20.02465","article-title":"Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective elderly project of the Fondazione Italiana Linfomi","volume":"39","author":"Merli","year":"2021","journal-title":"J Clin Oncol."},{"issue":"4","key":"2021092415294134300_B29","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood.2019000758","article-title":"Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies","volume":"134","author":"Liu","year":"2019","journal-title":"Blood."},{"issue":"5","key":"2021092415294134300_B30","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jgo.2015.07.006","article-title":"Identification of clinical parameters predictive of one-year survival using two geriatric tools in clinically fit older patients with hematological malignancies: major impact of cognition","volume":"6","author":"Dubruille","year":"2015","journal-title":"J Geriatr Oncol."},{"issue":"6","key":"2021092415294134300_B31","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00277-013-2001-0","article-title":"The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with a haematological malignancy","volume":"93","author":"Hamaker","year":"2014","journal-title":"Ann Hematol."},{"issue":"25","key":"2021092415294134300_B32","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/18\/3623\/1823513\/advancesadv2021004645.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/18\/3623\/1823513\/advancesadv2021004645.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T15:36:35Z","timestamp":1632497795000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/18\/3623\/476699\/Multicenter-analysis-of-geriatric-fitness-and-real"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,27]]},"references-count":32,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2021,9,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004645","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,27]]}}}